A_2B adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models

Abstract

Our results demonstrate that A_2BAR is a promising target in immunotherapy, identifying ISAM-R56A as the most potent candidate for A_2BAR blockade. Inhibition of A_2BAR signaling restores T cell function and proliferation. Furthermore, A_2BAR and dual A_2AAR/A_2BAR antagonists showed similar or better results than A_2AAR antagonist AZD-4635 reinforcing the idea of dominant role of the A_2BAR in the regulation of the immune system.